LGND - Ligand Pharmaceuticals Incorporated
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $1.46
|
Rev Est: $55.6M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$248.00
DETAILS
HIGH:
$275.00
LOW:
$230.00
MEDIAN:
$239.00
CONSENSUS:
$248.00
UPSIDE:
31.22%
Market Cap:
3.72B
Volume:
157,030
Avg Volume:
214,438
52 Week Range:
93.58-212.49
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.04
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
68
IPO Date:
1992-11-18
EPS (TTM):
-0.22
P/E Ratio:
-486.05
Revenue (TTM):
167.13M
Total Assets:
941.77M
Total Debt:
7.11M
Cash & Equiv:
72.31M
Rev Growth (5Y):
6.8%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
10.8%
ROCE:
0.6%
Debt/Equity:
0.01
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $3.09 | $1.97 | +56.9% | $115.5M | $55.6M | +107.7% |
| 2025-08-07 | $1.60 | $1.54 | +3.9% | $47.6M | $52.8M | -9.9% |
| 2025-05-08 | $1.33 | $1.30 | +2.3% | $45.3M | $44.3M | +2.3% |
| 2025-02-27 | $-1.64 | $1.37 | -219.7% | $42.8M | $35.3M | +21.3% |
| 2024-11-07 | $-0.39 | $0.75 | -152.0% | $51.8M | $39.0M | +32.8% |
| 2024-08-06 | $1.40 | $1.10 | +27.3% | $41.5M | $32.9M | +26.4% |
| 2024-05-07 | $1.20 | $1.13 | +6.2% | $31.0M | $27.9M | +11.0% |
| 2024-02-27 | $1.05 | $0.58 | +81.0% | $28.1M | $25.7M | +9.3% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 167.13M | 131.31M | 196.25M | 241.54M | 163.56M | 120.28M | 251.45M | 141.10M | 108.97M | 71.91M | 64.54M | 48.97M |
| Net Income | (4.03M) | 52.15M | (33.36M) | 57.14M | (2.98M) | 629.30M | 143.32M | 12.56M | (1.64M) | 257.31M | 12.02M | 11.42M |
| EPS | -0.22 | 3.02 | -1.98 | 3.46 | -0.18 | 33.13 | 5.96 | 0.60 | -0.08 | 13.00 | 0.59 | 0.56 |
| Total Assets | 941.77M | 787.22M | 762.67M | 1.30B | 1.36B | 1.49B | 1.26B | 671.02M | 601.59M | 533.93M | 258.03M | 104.71M |
| Total Debt | 7.11M | 6.17M | 87.75M | 324.39M | 456.41M | 650.18M | 636.30M | 224.53M | 212.91M | 205.37M | 196.24M | 9.11M |
| Cash & Equivalents | 72.31M | 22.95M | 45.01M | 19.52M | 47.62M | 71.54M | 718.38M | 201.66M | 141.05M | 200.22M | 167.34M | 15.98M |
| Operating Cash Flow | 97.05M | 49.58M | 137.85M | 78.80M | 54.59M | (29.34M) | 194.06M | 93.57M | 63.00M | 41.73M | 20.57M | 20.69M |
| Free Cash Flow | 77.41M | (4.27M) | 119.93M | 70.04M | 50.13M | (31.89M) | 182.17M | 86.41M | 34.68M | 30.86M | 16.07M | 15.75M |
| FCF per Share | 4.23 | -0.25 | 7.11 | 4.21 | 3.10 | -1.68 | 7.58 | 4.11 | 1.66 | 1.56 | 0.79 | 0.78 |
| Book Value | 830.44M | 700.91M | 597.49M | 821.16M | 709.52M | 767.23M | 560.91M | 418.65M | 370.85M | 304.39M | 26.32M | 49.61M |
| Cash & ST Investments | 256.17M | 170.31M | 211.87M | 341.11M | 411.19M | 1.07B | 764.57M | 201.66M | 141.05M | 200.22M | 167.34M | 15.98M |
| ROC Equity | -0.00 | 0.07 | -0.06 | 0.07 | -0.00 | 0.82 | 0.26 | 0.03 | -0.00 | 0.85 | 0.46 | 0.23 |